
The anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.
Dr. Andre Goy from John Theurer Cancer Center on Integrating Novel Therapies Into the JTCC Conference
Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses how novel treatment options have revolutionized treatment for patients with non-small cell lung cancer, a disease that used to be considered “beyond surgery.”
Novel therapies, new characterizations of tumors, and a more personalized approach to treating these tumors will be discussed at the upcoming


